Trelegy Ellipta is GSK’s once-daily triple-therapy inhaler, combining fluticasone furoate, umeclidinium and vilanterol in a single dry-powder device. It is prescribed as maintenance therapy for COPD and for asthma, and one inhaler is a 30-day supply.
Its pricing is unusual in one specific way: GSK publishes the list price on its own website, which most manufacturers do not, and GSK also runs a coupon that explicitly covers uninsured cash payers. That combination means the honest cash-price answer here is not one number but a spread from $35 to nearly $1,000, and which end you land on depends almost entirely on paperwork. Every figure below was verified on September 1 and 2, 2026.
What Does Trelegy Cost Without Insurance?
The list price comes from GSK’s own pricing page, which states its data is current as of January 1, 2026 and is based on pharmacy data analyzed from May 2025 through April 2026. Retail cash figures come from SingleCare’s live Trelegy Ellipta page, updated September 2, 2026, for the 100 mcg / 62.5 mcg / 25 mcg strength in a 60-blister inhaler.
| Option | Low | Average / typical | High |
|---|---|---|---|
| Trelegy, average retail cash (no card) | $966.66 | $966.66 | $966.66 |
| Trelegy, cash with a discount card | $554.10 (Kroger, Harris Teeter) | $628.51 (Costco) | $669.09 (Walmart Neighborhood Market) |
| GSK published list price, 30-day supply | $697.73 | $697.73 | $697.73 |
| GSKforYou inhaler savings offer | $35 | $35 | $35 |
| Trelegy commercial copay card | $0 | $0 | $0 |
| GSK Patient Assistance Program | $0 | $0 | $0 |
Note the disagreement between sources, because it matters. GSK says the list price is $697.73 for 30 days. SingleCare’s average retail cash price is $966.66, about $269 higher. Both are correct: list price is what the manufacturer charges wholesalers, while retail cash price includes the pharmacy’s markup on top of that. If you walk in with no card and no coupon, the retail number is the one you will be quoted, and the cross-source range for an uncovered fill is roughly $554 to $967.
The $35 inhaler cap, and its fine print
GSK announced in 2024 that it would cap out-of-pocket costs at no more than $35 per month for its entire U.S. asthma and COPD inhaler portfolio, to be implemented no later than January 1, 2025. Nine products are covered: Advair Diskus, Advair HFA, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta, Serevent Diskus, Trelegy Ellipta and Ventolin HFA.
The eligibility language on GSK’s posted coupon terms is the part worth reading twice. It states that patients may qualify if they have commercial insurance that does not cover the full cost, “or if they are not insured and are responsible for the cost of their prescriptions.” Eligible patients “will pay no more than $35 for each inhaler when the price charged for the product does not exceed the wholesale acquisition cost,” and the offer is valid for up to twelve uses per product, with each inhaler counting as one use.
Two cautions. First, anyone enrolled in a federal or state prescription program is excluded, including Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD and TRICARE, and the terms specify that you cannot get around this by asking the pharmacy to process you as a cash payer. Second, as of September 2026 the posted terms page carries a 2024 copyright and an expiration date of 12/31/2025. Confirm the current offer with GSK or your pharmacist before you count on the $35 price.
The copay card is a different program
Trelegy.com advertises paying “as little as $0” for up to 12 months, with a footnote defining maximum savings as wholesale acquisition cost less $35 per month. That is a copay card for eligible commercially insured patients, not a cash-payer program. If you are uninsured, the GSKforYou inhaler offer described above is the one to ask for by name.
What Drives the Price
There is no generic. SingleCare’s Trelegy page states plainly that no generic version is available in the U.S. and that the earliest one may appear is 2030. Without a generic or an authorized generic, there is no cheap equivalent to switch the prescription to, which is why manufacturer programs carry so much weight here.
Which pharmacy you use. SingleCare’s September 2026 data shows a $114.99 monthly swing between the cheapest and priciest major chains on the identical inhaler: $554.10 at Kroger and Harris Teeter, $594.78 at Publix, $628.51 at Costco, $651.78 at Walgreens and $669.09 at Walmart Neighborhood Market.
Whether you have a coupon at all. The difference between the average retail cash price and the GSK offer is roughly $932 per inhaler per month. Nothing else on this page comes close to that.
Your insurance type, not just whether you have insurance. Medicare and Medicaid enrollees are locked out of the manufacturer coupon entirely by federal anti-kickback rules, which is why some Medicare patients pay more out of pocket than uninsured patients do for the same inhaler.
Strength and device. Trelegy is sold in more than one strength. The prices above are for the 100/62.5/25 mcg 60-blister inhaler, the most commonly quoted presentation, so confirm the figure for the exact strength on your prescription.
Cash Price vs. Insurance
For an uninsured patient, the cash route with the GSK offer is almost certainly cheaper than any insurance-based path, and there is no scenario in which paying $966.66 retail is the right move if the coupon is available to you.
For an insured patient, it depends on plan design. If Trelegy sits on a preferred tier with a modest copay, use the insurance. If your plan applies a deductible, a coinsurance percentage or step therapy, the copay card can take the cost to $0 and the cash coupon can hold it at $35, either of which usually beats running the claim. The catch is that manufacturer assistance dollars often do not count toward your deductible or out-of-pocket maximum, and some plans run accumulator or maximizer programs specifically to capture that money, which also disqualifies you from the offer.
If a pharmacy quotes you a number that does not match anything on this page, our fair price checker is a quick way to see whether it is in a defensible range before you hand over a card.
How to Pay Less
-
Ask the pharmacist for the GSKforYou inhaler offer by name. Per GSK’s posted terms, eligible uninsured patients pay no more than $35 per inhaler, for up to twelve fills per product. This is the single highest-value step on the list, worth roughly $930 a month against average retail.
-
Price the exact strength at three pharmacies before you fill. The SingleCare spread above is $114.99 a month between chains on the same product. Our comparison of GoodRx vs. SingleCare explains how to check both cards on the same NDC in about two minutes.
-
Apply to the GSK Patient Assistance Program if the coupon is not open to you. It provides certain GSK medicines at no cost to patients who meet financial income criteria and who are uninsured or on Medicare, live in the U.S. or Puerto Rico, and are treated by a U.S. licensed provider. It is the main route for Medicare enrollees, who cannot use the coupon.
-
Do not assume brand list price equals your price. GSK’s own pricing page puts the 30-day list price at $697.73 while retail cash averages $966.66. If a pharmacy is charging well above list with no card applied, ask them to re-run it.
-
Budget for the rescue inhaler separately. Maintenance and rescue inhalers are billed as two prescriptions, and our guide to albuterol inhaler costs without insurance covers that side of the bill, including where Ventolin HFA falls under the same GSK $35 offer.
-
Get the prescribing visit priced too. A free or sliding-scale clinic can handle the visits that generate and renew the prescription at little or no cost, and if a pulmonology or hospital bill has already arrived, our medical bill negotiation guide covers what to say before paying it.
Bottom Line
Budget $554 to $967 for a 30-day Trelegy Ellipta inhaler if you pay cash with nothing but a discount card in September 2026, against a published GSK list price of $697.73. If you qualify for GSK’s inhaler savings offer, the number drops to $35, and a commercially insured patient using the Trelegy copay card can reach $0.
With no generic expected before 2030, the whole game here is which program you are eligible for, and the answer turns on your insurance type more than your income. Uninsured patients are, unusually, better positioned than Medicare enrollees on this particular drug. For other brand-only maintenance prescriptions with the same structure, see our guides to Entresto, Jardiance and Farxiga, and for the biologic end of the market, Humira shows what happens once cheaper equivalents finally arrive.